AXXESS PHARMA INC.
OTCPK: (AXXE)
COMPANY WEBSITE
Axxess Pharma Inc. Signs UFC Welterweight Fighter Tyron Woodley as Spokesperson
2014-09-02 08:00 ET - News Release
TORONTO, ON -- (Marketwired) -- 09/02/14
Axxess Pharma Inc. (PINKSHEETS: AXXE), a specialty pharmaceutical and nutritional supplements company, is pleased to announce through its wholly-owned subsidiary, AllStar Health Brands Inc., Tyron Woodley, UFC Welterweight fighter will be joining Axxess Pharma as spokesperson.
Tyron Woodley is a mixed martial artist who competes as a Welterweight for the Ultimate Fighting Championship (UFC). The Ultimate Fighting Championship (UFC) is the largest mixed martial arts promotion company in the world, which hosts all of the top-ranked fighters in the sport and produces events worldwide. Tyron Woodley's recent accomplishments include an 8-1 record in Strikeforce MMA. Soon after Strikeforce, he moved to the UFC where he executed an impressive 36-second KO of Jay Heiron -- and put the welterweight division on notice.
Tyron will work with AllStar Health Brands in aggressively marketing their TapouT line of all-natural Pain Relief and Muscle Growth products, including the Ready to Drink protein meal replacements. He will utilize his strong MMA following both in social media and at MMA fighting events.
Dr. Daniel Bagi, President of Axxess Pharma, stated: "We are extremely pleased to have Tyron Woodley represent our company. The TapouT brand is highly recognized and respected within the UFC and around the world. We look forward to Tyron expanding awareness of our TapouT line of Pain Relief and Muscle Growth products as well as our Ready to Drink protein meal replacements." Dr. Bagi further stated, "Unlike many protein drinks, we have developed our drinks to taste great. This is an important feature when comparing to market."
Read full Press Here
About Us
Axxess Pharma: a focused healthcare company dedicated to providing a wide range of products to improve the lives of patients and consumers worldwide.
We believe action defines leadership.
Our 23 wholly-owned prescription and non-prescription products are targeted to improve health-related conditions including several forms of iron deficiency, bone loss, rheumatoid arthritis, migraine headaches, urinary tract infections, infant cradle cap, joint pain and much more. Axxess Pharma intends to market these products with affordable pricing and widespread availability. Our company will continue to tap the well of innovation to develop ever-more effective and affordable treatment options for the patients we serve, and also foster innovation in education, leadership and advocacy.
Personal passion concerning the well-being of chronic illness sufferers is a major driving force and at the heart of our company. Affordable, proven, prescription and non-prescription products are a critical component to our company Business Plan. We balance environmental impact, social contribution, and financial results. Axxess Pharma is publicly traded on the US stock exchange under the ticker symbol: AXXE.
Products
Prescription Products
Britical Vivol
Gravergol Soropon
Somnol Kemsol
Lactrose Niaxx
Urasal Monurol
Axspaz Hydraxx
Non-Prescription Products
Triferex Syrup Hydraxx 2%
Triferex Pediatric Syrup Hydraxx Serum
Potassium Chloride liquid Hydraxx Serum Eyes
Calcium Citrate with VitaminD Kemsol for Scleroderma
Soropon Shampoo Triferex Capsules
Hydraxx 1%
High-dose oral iron supplement
Low side-effect oral iron
Severe anemia oral iron treatment
Oral iron with erythropoietin
Triferex the original high-dose oral iron supplement
Anemia and high-dose oral iron
Vegetarians and high-dose oral iron
Dialysis and high-dose oral iron
High-dose oral iron vs. Intravenous iron
Compliance issues in high-dose oral iron
Headache remedies
Migraine treatments
Treatment for migraines with nausea
Migraine medicines
Low-cost and effective migraine treatments
Cradle Cap remedies
Severe dandruff treatments
Cradle Cap shampoo
Seborrhoeic dermatitis treatments
Soropon Shampoo
Management
Daniel Bagi, M.D., President is a senior executive physician with 20+ year’s international experience in the medical device/pharmaceutical industry, with an emphasis on Product Development, Business Development and licensing. Expertise in product development as it pertains to clinical development for commercial use; medical affairs and clinical research, specifically oncology and gynecologic topical women’s health products. Good knowledge of international regulatory standards. Secured numerous license deals internationally, between North American pharma companies and local partners. Extensive experience presenting to financial institutions, regulatory agencies, and potential pharmaceutical partners.
Neil Mellor, Senior VP Sales, has over 25 years of pharmaceutical experience both in Canada and in Europe. Neil has worked for large companies such as Merck, GSK and Pfizer and has also worked with medium-sized pharma companies such as Solvay Pharma. Neil has spent the majority of his background in sales, marketing and business development and has been involved with over thirty products in numerous therapeutic areas. Neil brings a great deal of first-hand experience in commercializing products. In addition, during 2008 Neil was President of the Canadian Healthcare Licensing Association (CHLA) and currently serves as a CHLA Board member. From 1999 to 2004 Neil was Senior Product Manager for Pantoloc®, a proton pump inhibitor used to treat heartburn. During this time Pantoloc exceeded $200m in annual sales and was listed by IMS as the fourth largest pharmaceutical product in Canada. Prior to Solvay, Neil spent 3 years working with Pharmacia Consumer Healthcare (now Pfizer) in Sweden working in International marketing for the brand Nicorette®.
Stephen Taylor, Investor/Business Relations: CEO/Pres. of Taylor Capitol, Inc., has provided Investor Relation services for years with a prior background in equity research and investment banking in the Wall Street area. Stephen Taylor possesses a deep network of connections in the investment community. This network ranges from retail brokers, fund managers, wealth managers, Wall Street analysts, investment bankers, private equity firms and senior level management consultants.
AXXE Security Details
Share Structure
Market Value1 $12,746,909 a/o Oct 15, 2013
Shares Outstanding 43,209,861 a/o Sep 25, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Sep 25, 2013
Tuesday, September 17, 2013
Axxess Pharma Inc. Acquires Existing Revenues, Patents, Formulations and NFL, NHL, UFC Athlete Endorsed Products From Leading Canadian OTC Healthcare CompanyMarketwired( (Tue, Sep 17)
Monday, September 16, 2013
Axxess Pharma Inc. Bolsters Management With Key Addition to Sales & Marketing TeamMarketwired( (Mon, Sep 16)
Thursday, September 12, 2013
Axxess Pharma Inc. President, Daniel Bagi, M.D. Provides Exclusive Interview on StockTradersTalk.comMarketwired( (Thu, Sep 12)
Wednesday, September 11, 2013
Axxess Pharma Inc. Initiates Next Step Towards Bulletin Board (OTCBB) ListingMarketwired( (Wed, Sep 11)
Monday, September 9, 2013
AXXESS Pharma Inc. Signs Agreement With Top Mexican Pharmaceutical CompanyMarketwired( (Mon, Sep 9)
Wednesday, September 4, 2013
Axxess Pharma Inc. Announces US Board Certified Cardiologist, Dr. Fred Maese as Senior ConsultantMarketwired( (Wed, Sep 4)
Monday, September 2, 2013
Axxess Pharma Inc. Announces MOU to Acquire Leading Canadian OTC Healthcare CompanyMarketwired( (Mon, Sep 2)
Wednesday, August 14, 2013
Axxess Pharma Inc. Announces Two-Time Canadian Heavyweight Boxing Champion Ray Olubowale as Spokesperson and Corporate AmbassadorMarketwired( (Wed, Aug 14)
Thursday, August 1, 2013
AXXESS Pharma, Inc. Announces License Agreement with Canadian Manufacturer of Cancer DrugsAccesswire( (Thu, Aug 1)
Tuesday, July 23, 2013
Axxess Pharma, Inc. Announces MOU for Exclusive World-Wide License Rights for TapouT Brand Vitamins and Pain Relief ProductsAccesswire( (Tue, Jul 23)
Wednesday, July 17, 2013
Dr. Daniel Bagi, President and CEO of Axxess Pharma, Inc., is Featured in a New Audio Interview at SmallCapVoice.comGlobeNewswire( (Wed, Jul 17)
Tuesday, July 16, 2013
Axxess Pharma Inc. in Discussions for World-Wide Rights with Leading Sporting BrandAccesswire( (Tue, Jul 16)
Wednesday, July 10, 2013
Axxess Pharma, Inc. Announces Key Addition to Management with Appointment of Senior Vice President of Sales & MarketingAccesswire( (Wed, Jul 10)
Disclaimer: pennystockdivas.com is wholly owned by Global Innovator Relations LLC. This email and the content provided is intended for advertisement purposes only. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our e-mail list. PLEASE NOTE: Global Innovator Relations, LLC and pennystockdivas.com employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at http://pennystockdivas.com/disclaimer.php Release of Liability: Through use of this website/newsletter viewing or using you agree to hold pennystockdivas.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources, which we believe to be reliable, but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Pennystockdivas.com’s affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Pennystockdivas.com encourages readers and investors to supplement the information in these reports with independent research and other pro advice. All information on featured companies is provided by the companies profiled, or is available from public sources and pennystockdivas.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Pennystockdivas.com often receives compensation for marketing, awareness and investor relation services, which can be reviewed within our disclaimer. Pennystockdivas.com has been compensated $1500 by a non controlling third party for the release of this newsletter . Pennystock divas has been previously compensated by a non controlling third party for other services. Pennystockdivas.com, Global Innovator Relations, LLC nor any of its affiliates are not registered investment advisors or broker dealers.
